Patient Characteristics
| Characteristic | n | % |
| Mean age (y) | 64 | |
| Sex | ||
| Female | 11 | 85 |
| Male | 2 | 15 |
| Primary tumor characteristics IHC | ||
| ER+/AR+ | 13 | 100 |
| ER+/AR− | 0 | |
| ER−/AR+ | 0 | |
| ER−/AR− | 0 | |
| Primary tumor stage | ||
| T1N0M0 | 4 | 31 |
| T1N1M0 | 1 | 8 |
| T2N0M0 | 4 | 31 |
| T2N1M0 | 1 | 8 |
| T3N2M0 | 3 | 23 |
| Metastatic tumor characteristics IHC | ||
| ER+/AR+ | 10 | 77 |
| ER+/AR− | 1 | 8 |
| ER−/AR+ | 1 | 8 |
| ER−/AR− | 1 | 8 |
| Treatment at time of 18F-FES and 18F-FDHT PET scans | ||
| Aromatase inhibitor | 5 | 38 |
| Chemotherapy | 4 | 31 |
| None | 4 | 31 |
ER+ = ER-positive; AR+ = AR-positive; ER− = ER-negative; AR− = AR-negative; IHC = immunohistochemistry.